PSG In Lab denied as non-formulary by Aetna?

Aetna's specific coverage criteria for psg in lab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issues a Non-Formulary Denial for In-Lab PSG

In-lab polysomnography is a procedure, not a drug, so a "non-formulary" denial in this context typically means Aetna has determined the service falls outside its covered benefit schedule, or that it is classified as a non-preferred service tier requiring additional justification. This is distinct from a true medical-necessity dispute: the plan is saying the service category itself is not straightforwardly covered, rather than questioning your clinical need.

These denials are frequently overturned because attended in-lab PSG has a well-established clinical evidence base and is recognized by major professional sleep medicine societies as the reference standard for diagnosing complex or ambiguous sleep-disordered breathing.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 guarantee you a full-and-fair internal review. Aetna must explain precisely which benefit exclusion or formulary classification applies.
• External review: Independent external review is available after the internal process is exhausted. The filing window is generally open for approximately four months after final internal denial.
• Expedited track: If your condition is clinically urgent, an expedited review path with a condensed decision timeline is available.

## Documentation to Gather

1. Benefit plan documents — obtain your Summary Plan Description and Schedule of Benefits to verify whether in-lab PSG is explicitly excluded or merely non-preferred. 2. Physician letter of medical necessity — your ordering clinician should explain why the specific clinical indications require an in-lab study and reference current AASM guidance. 3. Diagnosis and clinical history — chart notes establishing the presenting complaint, relevant comorbidities, and any prior failed or inconclusive home sleep testing. 4. Applicable guideline citation — your physician should note which AASM or other professional-society guidance supports attended PSG for your clinical scenario.

## Criteria-Mapping Structure

Request Aetna's written explanation of the specific non-formulary or benefit-exclusion language it applied. Then address each clause directly:

| Aetna Exclusion/Limitation Language | Your Response and Supporting Evidence | |---|---| | [Paste the exact language from the denial] | [Cite the plan document, guideline, or chart note that rebuts or limits the exclusion] |

## Next Step

Confirm with your plan administrator whether in-lab PSG is excluded, non-preferred, or simply requires additional authorization. Many non-formulary denials resolve at the internal appeal stage once the clinical record fully responds to the specific classification issue Aetna identified.